Adherium Limited announced that it has commenced production and market release of the new, next generation Hailie® sensors with physiological
parameters connecting GlaxoSmithKline (GSK) ELLIPTA® inhalers for monitoring Asthma and Chronic Obstructive Pulmonary Disease (COPD). This product rollout adds to Adherium's growing Hailie sensor portfolio in the market with US FDA 510(k) clearances. Adherium offers the only 510(k) cleared sensor on the market with respiratory flow rate data and adherence tracking feedback at the time of medication use.